Repare backer Amplitude Ventures unveils $192M biotech fund

2024-05-29

Preview

来源: FierceBiotech

Amplitude Ventures has already put down four of up to 16 planned investments from the new fund.

Repare Therapeutics backer Amplitude Ventures has unveiled a second fund, securing $192 million that will be dedicated to the development of new precision medicines.

The Canada-based VC will channel the cash toward companies that incorporate both biology and artificial intelligence in drug development. Since 2019, Amplitude has set out to create and build companies, including Repare Therapeutics, which IPO'ed in 2020 and was one of Canada’s largest biotech public market debuts at the time.

Amplitude has already put down four of up to 16 planned investments from the new fund, funneling money to inflammatory-disease-focused Evommune; conditional multi-specifics company Tentarix Biotherapeutics; antibody-based platform biotech Reverb Therapeutics; and antibody discovery company Evolved Therapeutics.

The VC also inked (PDF) a partnership with Germany-based Evotec back in October 2023. Amplitude’s venture studio, dubbed Pre-Amp, is slated to use Evotec’s drug discovery platform to accelerate the formation of new companies.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构